Please use this identifier to cite or link to this item:
|Title:||A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)|
|Author:||Van Vollenhoven, Ronald F.|
Voskuyl, Alexandre E.
Balá ová, Petra
Bruce, Ian N.
Cervera i Segura, Ricard, 1960-
Clarke, Ann E.
Derksen, R. H. W. M.
Houssiau, Frédéric A.
Le Guern, Véronique
Levy, Roger A.
Estudi de casos
|Publisher:||BMJ Publishing Group|
|Abstract:||Objectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2016-209519|
|It is part of:||Annals of the Rheumatic Diseases, 2016, vol. 76, num. 3, p. 554-561|
|Appears in Collections:||Articles publicats en revistes (Medicina)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.